Directed shift of vaginal flora after topical application of sucrose gel in a phase III clinical trial: A novel treatment for bacterial vaginosis

Chinese Medical Journal

Volumn 123, Issue 15, 2010, Pages 2051-2057

  Zeng, Zhong Ming ^a   Liao, Qin Pin ^b   Yao, Chen ^b   Geng, Li ^c   Feng, Li Hua ^d   Shi, Hui Rong ^e   Xin, Xiao Yan ^f   Li, Ping ^g   Wang, Hui Lan ^h   Pang, Yi Cun ^h   Liu, Shu Wen ⁱ   Jiang, Shi Bo ^j  

^a GUANGDONG MEDICAL UNIVERSITY   (China)

^b PEKING UNIVERSITY FIRST HOSPITAL   (China)

^c PEKING UNIVERSITY THIRD HOSPITAL   (China)

^d THE FIRST HOSPITAL OF JILIN UNIVERSITY   (China)

^e THE FIRST AFFILIATED HOSPITAL OF ZHENGZHOU UNIVERSITY   (China)

^f FOURTH MILITARY MEDICAL UNIVERSITY   (China)

^g NANJING MEDICAL UNIVERSITY   (China)

^h HEBEI MEDICAL UNIVERSITY   (China)

ⁱ SOUTHERN MEDICAL UNIVERSITY   (China)

^j NEW YORK BLOOD CENTER   (United States)

more..

Author keywords

Bacterial vaginosis; Clinical trial; Metronidazole; Sucrose; Vaginal flora

Indexed keywords

METRONIDAZOLE; PLACEBO; SUCROSE;

ABDOMINAL DISTENSION; ABDOMINAL PAIN; ARTICLE; BACTEROIDES; BEDTIME DOSAGE; CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; GARDNERELLA VAGINALIS; HUMAN; LACTOBACILLUS; LOW BACK PAIN; MAJOR CLINICAL STUDY; MOBILUNCUS; MORNING DOSAGE; MULTICENTER STUDY; MYCOSIS; PARALLEL DESIGN; PHASE 3 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM; VAGINA FLORA; VAGINITIS;

ADMINISTRATION, INTRAVAGINAL; ADOLESCENT; ADULT; ANTI-BACTERIAL AGENTS; DOUBLE-BLIND METHOD; FEMALE; HUMANS; METRONIDAZOLE; MIDDLE AGED; SUCROSE; TREATMENT OUTCOME; VAGINOSIS, BACTERIAL; YOUNG ADULT;

EID: 77956124837     PISSN: 03666999     EISSN: None     Source Type: Journal    
DOI: 10.3760/cma.j.issn.0366-6999.2010.15.018     Document Type: Article

References (22)

1. Sobel JD. Vaginitis. N Engl J Med 1997; 337: 1896-1903.
2. Hillier SL, Nugent RP, Eschenbach DA, Krohn MA, Gibbs RS, Martin DH, et al. The Vaginal Infections and Prematurity Study Group. Association between bacterial vaginosis and preterm delivery of a low-birth-weight infant. N Engl J Med 1995; 333: 1737-1742.
3. Peipert JF, Ness RB, Blume J, Soper DE, Holley R, Randall H, et al. Clinical predictors of endometritis in women with symptoms and signs of pelvic inflammatory disease. Am J Obstet Gynecol 2001; 184: 856-864.
4. Wiesenfeld H, Hillier S, Krohn M, Landers D, Sweet R. Bacterial vaginosis is a strong predictor of neisseria gonorrhoeae and chlamydia trachomatis Infection. Clin Infect Dis 2003; 36: 663-668.
5. Watts DH, Fazarri M, Minkoff H, Hillier SL, Sha B, Glesby M, et al. Effects of bacterial vaginosis and other genital infections on the natural history of human papillomavirus infection in HIV-infected and high-risk HIV-uninfected women. J Infect Dis 2005; 191: 1129-1139.
6. Cherpes T, Meyn L, Krohn M, Lurie J, Hillier S. Association between acquisition of herpes simplex virus type 2 in women and bacterial vaginosis. Clin Infect Dis 2003; 37: 319-325.
7. Martin HL, Richardson BA, Nyange PM, Lavreys L, Hillier SL, Chohan B, et al. Vaginal lactobacilli, microbial flora, and risk of human immunodeficiency virus type 1 and sexually transmitted disease acquisition. J Infect Dis 1999; 180: 1863-1868.
8. Eckert LO. Acute vulvovaginitis. N Engl J Med 2006; 355: 1244-1252.
9. Plourd DM. Practical guide to diagnosing and treating vaginitis. Medsc Gen Med 1999; 2: 2.
10. Beigi RH, Austin MN, Meyn LA, Krohn MA, Hillier SL. Antimicrobial resistance associated with the treatment of bacterial vaginosis. Am J Obstet Gynecol 2004; 191: 1124-1129.
11. Finch R, Sharland M. 18 November and beyond: observations on the EU Antibiotic Awareness Day. J Antimicrob Chemother 2009; 63: 633-635.
12. Amsel R, Totten PA, Spiegel CA, Chen KC, Eschenbach D, Holmes KK. Nonspecific vaginitis. Diagnostic criteria and microbial and epidemiologic associations. Am J Med 1983; 74: 14-22.
13. Clinical Effectiveness Group, British Association for Sexual Health and HIV (BASHH). London (UK): British Association for Sexual Health and HIV (BASHH); 2006: 4.
14. Nugent RP, Krohn MA, Hillier SL. Reliability of diagnosing bacterial vaginosis is improved by a standardized method of gram stain interpretation. J Clin Microbiol 1991; 29: 297-301.
15. Cohrssen A, Anderson M, Merrill A, McKee D. Reliability of the Whiff test in clinical practice. J Am Board Fam Pract 2005; 18: 561-562.
16. U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER). Guidance for industry: bacterial vaginosis-developing antimicrobial drugs for treatment. Draft guidance. July, 1998. (Accessed at May 24, 2007 www.fda.gov/cder/guidance/2572dft.pdf.)
17. Schwebke J, Desmond R. A randomized trial of the duration of therapy with Metronidazole plus or minus Azithromycin for treatment of symptomatic bacterial vaginosis. Clin Infect Dis 2007; 44: 213-219.
18. Simoes JA, Aroutcheva AA, Shott S, Faro S. Effect of metronidazole on the growth of vaginal lactobacilli in vitro. Infect Dis Obstet Gynecol 2001; 9: 41-45.
19. Royce RA, Sena A, Cates W, Cohen MS. Sexual transmission of HIV. N Engl J Med 1997; 336: 1072-1078.
20. Fauci AS. 25 years of HIV. Nature 2008; 453: 289-290.
21. Rebbapragada A, Howe K, Wachini C, Pettengell C, Sunderji S, Huibner S, et al. Bacterial vaginosis in HIV infected women induces reversible alterations in the cervical immune environment. J Acquir Immune Defic Syndr 2008; 49: 520-522.
22. Moodley P, Connolly C, Stum AW. Interrelationships among human immunodeficiency virus type 1 infection, bacterial vaginosis, trichomoniasis, and the presence of yeasts. J Infect Dis 2002; 185: 69-73.